(Q46413574)

22 December 2017

title

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder (English)

1 reference

22 December 2017

oppositional defiant disorder

1 reference

0 references

1 reference

S Kaplan

1

1 reference

22 December 2017

J Heiligenstein

2

1 reference

22 December 2017

S West

3

1 reference

22 December 2017

J Busner

4

1 reference

22 December 2017

D Harder

5

1 reference

22 December 2017

R Dittmann

6

1 reference

22 December 2017

C Casat

7

1 reference

22 December 2017

J F Wernicke

8

1 reference

22 December 2017

publication date

1 October 2004

1 reference

22 December 2017

Journal of Attention Disorders

published in

1 reference

22 December 2017

volume

8

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

45-52

1 reference

22 December 2017

Persistence and desistance of oppositional defiant disorder in a community sample of children with ADHD.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

Attention-deficit/hyperactivity disorder and associated childhood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

Affective valence and arousal in ADHD and normal boys during a startle habituation experiment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F108705470400800202

10.1177/108705470400800202

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017